Advice
Following a full submission:
midazolam oromucosal solution (Buccolam®) is accepted for use within NHS Scotland.
Indication under review: Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to <18 years).
Midazolam given via the buccal route was considered at least non-inferior to rectally administered benzodiazepine in terminating acute prolonged seizures.
The economic case was demonstrated for midazolam oromucosal solution (Buccolam®) compared to rectal diazepam.
Download detailed advice159KB (PDF)
Medicine details
- Medicine name:
- midazolam (Buccolam oromucosal solution)
- SMC ID:
- 757/12
- Indication:
- For the treatment of prolonged , acute, convulsive seizures in infants, children and adolescents.
- Pharmaceutical company
- ViroPharma Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 13 February 2012